Business
AngioDynamics to Participate in Three Investor Conferences in March
LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy
About this update from Angiodynamics, Inc.
[{"type":"text","content":" LATHAM, N.Y.--(BUSINESS WIRE)--\nAngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in the following three investor conferences in March:\n\nRaymond James Institutional Investors Conference\nFormat: In-person Presentation\nDate: Monday, March 6, 2023\nTime: 8:05 a.m. ET\nLocation: Orlando, FL\n\nOppenheimer Virtual Healthcare Conference\nFormat: Fireside Chat\nDate: Monday, March 13, 2023\nTime: 9:20 a.m. ET\n\nKeyBanc Virtual Life Sciences & MedTech Investor Forum\nFormat: Fireside Chat\nDate: Tuesday, March 21, 2023\nTime: 4:30 p.m. ET\n\nA live webcast of each presentation will be accessible through the “Investors” section of the Company’s website at www.angiodynamics.com and will be available for replay following each event.\n\nAbout AngioDynamics, Inc.\n\nAngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients.\n\nThe Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20230228005538/en/\n\nInvestor:\n\nAngioDynamics, Inc.\nStephen Trowbridge, Executive Vice President & CFO\n(518) 795-1408\n\nSource: AngioDynamics, Inc.","length":3582,"tagName":"div"}]